{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "10000807",
    "licUnit": "1",
    "validDate": "2030-05-24 00:00:00.000",
    "issueDate": "2005-05-24 00:00:00.000",
    "oriIssueDate": "2005-05-24",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA01000080706",
    "prodNameC": "癌思停 注射劑",
    "prodNameE": "AVASTIN INJECTION",
    "indicationsName": [
        "1. 轉移性大腸直腸癌 (mCRC)：\r\nAvastin (bevacizumab) 與含有5-fluorouracil為基礎的化學療法合併使用，可以作為轉移性大腸或直腸癌病人的第一線治療。\r\nAvastin與含有5-fluorouracil\/leucovorin\/oxaliplatin的化學療法合併使用，可以作為先前接受過以fluoropyrimidine為基礎的化學療法無效且未曾接受過Avastin治療的轉移性大腸或直腸癌病人的治療。\r\nAvastin (bevacizumab) 與含有fluoropyrimidine-irinotecan-或fluoropyrimidine-oxaliplatin-為基礎的化學療法合併使用，可以做為第一線已接受過以Avastin併用化療後惡化之轉移性大腸或直腸癌病人的第二線治療。\r\n2. 轉移性乳癌 (mBC)：\r\nAvastin與paclitaxel合併使用，可以做為HER2 (-) 轉移性乳癌病人的第一線治療。\r\n3. 惡性神經膠質瘤（WHO第4級）-神經膠母細胞瘤：\r\nAvastin單獨使用可用於治療曾接受標準放射線治療且含temozolomide在內之化學藥物治療失敗之多型性神經膠母細胞瘤 (Glioblastoma multiforme) 復發之成人病人。\r\n4. 晚期、轉移性或復發性非鱗狀非小細胞肺癌 (NSCLC)：\r\nAvastin與carboplatin及paclitaxel合併使用，可以作為無法切除的晚期、轉移性或復發性非鱗狀非小細胞肺癌病人的第一線治療。\r\nAvastin併用erlotinib，可作為無法手術切除的晚期、轉移性或復發性且帶有表皮生長因子受體 (EGFR) 活化性突變的非鱗狀非小細胞肺癌病人的第一線治療。\r\n5. 卵巢上皮細胞、輸卵管或原發性腹膜癌 (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer)：\r\nAvastin與carboplatin及paclitaxel合併使用，接著單獨使用Avastin，可以做為第三期或第四期卵巢上皮細胞、輸卵管或原發性腹膜癌病人接受初次手術切除後之治療。\r\nAvastin與carboplatin及gemcitabine合併使用，可以做為曾接受過第一線含鉑類藥物 (platinum-based) 化學治療間隔至少6個月再復發（即，對含鉑藥物具感受性），且未曾接受過bevacizumab或其他血管內皮細胞生長因子 (VEGF) 抑制劑或血管內皮細胞生長因子接受器之標靶藥物 (VEGF receptor-targeted agents) 治療之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。\r\nAvastin與carboplatin及paclitaxel合併使用，接著單獨使用Avastin治療，可以做為對含鉑藥物具感受性之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。\r\nAvastin併用paclitaxel、topotecan或pegylated liposomal doxorubicin可以做為接受過含鉑類藥物 (platinum-based) 化療治療後6個月內再復發（即，對含鉑藥物具抗藥性）、之前接受不超過2種化療療程且未曾接受過bevacizumab或其他血管內皮細胞生長因子 (VEGF) 抑制劑或血管內皮細胞生長因子接受器之標靶藥物 (VEGF receptor-targeted agents) 之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。\r\n6. 持續性、復發性或轉移性之子宮頸癌 (Persistent, Recurrent, or Metastatic Cervical Cancer)：\r\nAvastin與paclitaxel及cisplatin合併使用可用於治療持續性、復發性或轉移性之子宮頸癌。Avastin與paclitaxel及topotecan合併使用可用於無法接受含鉑類藥物治療 (platinum therapy) 病人之持續性、復發性或轉移性子宮頸癌。"
    ],
    "does": "2270",
    "packageUnit": [
        {
            "packageSpec": "4毫升,16毫升",
            "packageUnit": "13"
        },
        {
            "packageSpec": "100小瓶以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": null,
    "medDCode": null,
    "mainCategory": null,
    "drBaseId": "96C240A8-EB3A-4066-8FB5-665E160EB527",
    "subCategory": [],
    "ingredientsDesc": [
        "BEVACIZUMAB"
    ],
    "restraintItemsCode": [
        "02 輸 入",
        "55 依本署89、12、12衛署藥字第0890035812號公告事項三經本署認定得免除銜接性試驗之新藥",
        "67 成品已完成元素不純物評估(Option 1、2a、2b)"
    ],
    "applicantName": "羅氏大藥廠股份有限公司",
    "applicantAddr": "台北市南港區經貿一路170號10樓、10樓之1至之3、10樓之5至之8",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": null,
    "mdKind": [],
    "monitorDate": null,
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "id": "9C5BE95E-6C8C-4A73-A9E9-8CBA4968CACE",
            "factoryCode": "1",
            "factoryName": "F. HOFFMANN-LA ROCHE LTD.",
            "factoryAddr": "WURMISWEG, CH-4303 KAISERAUGST, SWITZERLAND",
            "factoryCompanyAddr": null,
            "countryCode": "CH",
            "processCode": [
                {
                    "value": "66",
                    "name": "成品製造廠"
                }
            ],
            "processCodeStr": "66;成品製造廠",
            "factoryKind": "M",
            "factoryNo": "FCH0257000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "6B63A805-0CDD-43F1-8D3F-F434C08119B7",
            "factoryCode": "1",
            "factoryName": "ROCHE DIAGNOSTICS GMBH",
            "factoryAddr": "SANDHOFER STRASSE 116 D-68305 MANNHEIM GERMANY",
            "factoryCompanyAddr": null,
            "countryCode": "DE",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FDE0261000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "7B27BBEC-E627-41B4-9A64-D28D723FDBF4",
            "factoryCode": "1",
            "factoryName": "GENENTECH INC.",
            "factoryAddr": "4625 NE BROOKWOOD PARKWAY, HILLSBORO OREGON, 97124 USA",
            "factoryCompanyAddr": "",
            "countryCode": "US",
            "processCode": [
                {
                    "value": "66",
                    "name": "成品製造廠"
                }
            ],
            "processCodeStr": "66;成品製造廠",
            "factoryKind": "M",
            "factoryNo": "FUS0767100",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "F91B31A8-D759-4E46-BA48-76857721BE63",
            "factoryCode": "2",
            "factoryName": "F. HOFFMANN-LA ROCHE LTD.",
            "factoryAddr": "GRENZACHERSTRASSE 124, CH-4070 BASEL, SWITZERLAND",
            "factoryCompanyAddr": null,
            "countryCode": "CH",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FCH0258000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "7DB63696-04E4-4982-98F4-983AF67EDA62",
            "factoryCode": "2",
            "factoryName": "Roche Singapore Technical Operations Pte.Ltd.",
            "factoryAddr": "10 Tuas Bay Link, 637394 Singapore",
            "factoryCompanyAddr": "",
            "countryCode": "SG",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FSG0030000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "9C6F3B49-E2B3-49DA-B4BC-EDDF86F31130",
            "factoryCode": "2",
            "factoryName": "GENENTECH, INC.",
            "factoryAddr": "1 ANTIBODY WAY, OCEANSIDE, CA 92056, USA",
            "factoryCompanyAddr": null,
            "countryCode": "US",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FUS0768000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013000800",
            "ingredientsName": "BEVACIZUMAB",
            "ingredientsDesc": "BEVACIZUMAB",
            "concentDesc": null,
            "concent": "25.0000",
            "concentUnit": "001",
            "seq": "6",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FG01"
        }
    ],
    "licBaseId": "34CA6E6C-E810-48A3-A562-1627A9E83717"
}